• Clinical asset planned to be advanced in Lupus Nephritis and other indications
  • Program includes first-in-class integrin activator for myeloid cell integrin CD11b
  • CD11b activation reduces myeloid overactivation and tissue damage
  • Target validated in multiple auto-immune diseases and oncology

Miami, FL, February 23, 2023 (PRWeb) – 149 Bio, LLC, a clinical-stage therapeutics company focused on developing breakthrough treatments for kidney diseases and other immune conditions with high unmet need, announced today that it has acquired GB1275, a first-in-class orally bioavailable integrin activator, and the associated CD11b program in its entirety from Gossamer Bio, Inc.

The company plans to advance GB1275 in multiple therapeutic indications, including Lupus Nephritis (LN). GB1275 has the potential to reduce innate immune cell driven autoimmunity in multiple therapeutic areas and significantly improve patients’ lives. It is the first of its kind integrin activator to have entered the clinic.

“Over-exuberant innate immune cell response incites autoimmunity and end-organ injury in multiple autoimmune diseases, such as Systemic Lupus Erythematosus (SLE) and Lupus Nephritis. Targeting key integrin receptor CD11b via the highly novel integrin activator GB1275 has been shown to significantly reduce myeloid cell activity in circulation and leukocyte infiltration in tissues, thereby reducing autoimmune damage,” said 149 Bio founder and CEO Vineet Gupta, PhD.

He continues that, “the acquisition of GB1275 and associated CD11b program, a potentially transformative therapeutic mechanism for autoimmune diseases and other indications, is consistent with our strategy to develop highly differentiated therapeutics to target integrin receptors in a variety of disease areas. We are especially focused on developing novel therapeutics for kidney diseases, to improve care for patients with urgent, unmet needs in these areas.”

The terms of the agreement were not publicly disclosed.

About 149 Bio, LLC

149 Bio is a privately held therapeutics company that is focused on targeting integrin receptors with a highly differentiated mechanism of action – allosteric activation. The company is leveraging pioneering discoveries of its co-founder Vineet Gupta, PhD, who was among the first to develop allosteric activators of integrins. Dr. Gupta’s research has shown that this is a highly differentiated therapeutic modality for targeting integrins. The company has also developed a proprietary CellStaple platform that enables discovery and validation of novel candidates. The company is using this platform for rapid identification and development of allosteric agonists against multiple different integrin targets and has a pipeline of different therapeutic programs in various stages of development.

Investor and Media Contact:

Santiago Balza Pineda